Stay updated on Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Sign up to get notified when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.

Latest updates to the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe page footer shows an updated ClinicalTrials.gov revision identifier from v3.5.2 to v3.5.3, indicating a system/version update without changing the study details.SummaryDifference0.0%

- Check26 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check55 days agoChange DetectedRevision label updated to v3.5.0 (from v3.4.3).SummaryDifference0.0%

- Check69 days agoChange DetectedRevision label updated to v3.4.3. The previous label v3.4.2 has been removed.SummaryDifference0.0%

- Check91 days agoChange DetectedThe page now displays Revision: v3.4.2, replacing Revision: v3.4.1. This appears to be a minor maintenance update and does not change study information; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check98 days agoChange DetectedSite revision updated from v3.4.0 to v3.4.1. This change does not affect any study details, eligibility criteria, results, or timeframes.SummaryDifference0.0%

Stay in the know with updates to Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nanoliposomal Irinotecan vs Nab-paclitaxel/Gemcitabine Clinical Trial page.